Search results for "GLYCOSAMINOGLYCANS"

showing 10 items of 57 documents

Production of Injectable Marine Collagen-Based Hydrogel for the Maintenance of Differentiated Chondrocytes in Tissue Engineering Applications

2020

Cartilage is an avascular tissue with limited ability of self-repair. The use of autologous chondrocyte transplants represent an effective strategy for cell regeneration

0301 basic medicineAquatic OrganismsScyphozoaCytoskeleton organizationchondrocytes02 engineering and technologychondrocytes differentiationGelatinRegenerative medicinelcsh:ChemistryMiceTissue engineeringcartilagelcsh:QH301-705.5CytoskeletonSpectroscopyGlycosaminoglycansChemistryCell DifferentiationHydrogelsdifferentiationGeneral Medicine021001 nanoscience & nanotechnologyComputer Science ApplicationsCell biologymedicine.anatomical_structurejellyfish collagenenzymatic cross-linkingchondrocyteCollagen0210 nano-technologyfood.ingredientCell Survivalregenerative medicineArticleCatalysisChondrocyteCell LineInjectionsInorganic Chemistry03 medical and health sciencesfoodmedicineAnimalsPhysical and Theoretical ChemistryMolecular BiologyTissue EngineeringRegeneration (biology)CartilageOrganic ChemistryChondrogenesisRats030104 developmental biologyGene Expression Regulationlcsh:Biology (General)lcsh:QD1-999gene expressionCattlecomposite injectable hydrogelInternational Journal of Molecular Sciences
researchProduct

Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models

2020

International audience; Mucopolysaccharidoses are a class of lysosomal storage diseases, characterized by enzymatic deficiency in the degradation of specific glycosaminoglycans (GAG). Pathological accumulation of excess GAG leads to multiple clinical symptoms with systemic character, most severely affecting bones, muscles and connective tissues. Current therapies include periodic intravenous infusion of supplementary recombinant enzyme (Enzyme Replacement Therapy-ERT) or bone marrow transplantation. However, ERT has limited efficacy due to poor penetration in some organs and tissues. Here, we investigated the potential of the β-D-xyloside derivative odiparcil as an oral GAG clearance therap…

0301 basic medicineMaleMucopolysaccharidosis type VIRespiratory SystemAdministration OralGlycosaminoglycanRats Sprague-DawleyWhite Blood CellsMice0302 clinical medicineOral administrationAnimal CellsMedicine and Health SciencesGlycosidesCells CulturedConnective Tissue CellsGlycosaminoglycansMultidisciplinaryMucopolysaccharidosis VIChemistryChondroitin SulfatesQRMucopolysaccharidosis VIAnimal Models3. Good healthTracheamedicine.anatomical_structureExperimental Organism SystemsConnective Tissue[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyMedicineFemaleBiological CulturesCellular TypesAnatomyCellular Structures and OrganellesResearch Articlemedicine.medical_specialtyImmune CellsScienceImmunologyDermatan SulfateMouse ModelsIn Vitro TechniquesResearch and Analysis Methods03 medical and health sciencesModel OrganismsIn vivoInternal medicinemedicineAnimalsHumansBlood CellsCartilageBiology and Life SciencesEndothelial CellsKidneysCell BiologyRenal SystemFibroblastsCell CulturesIn vitroMice Mutant StrainsRatsMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyBiological TissueCartilageCell cultureAnimal Studies[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyCattleLysosomes030217 neurology & neurosurgery
researchProduct

Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort

2016

Background: Although survival for neuroblastoma patients has dramatically improved in recent years, a substantial number of children in the high-risk subgroup still die. Methods: We aimed to define a subgroup of ultra-high-risk patients from within the high-risk cohort. We used advanced morphometric approaches to quantify and characterise blood vessels, reticulin fibre networks, collagen type I bundles, elastic fibres and glycosaminoglycans in 102 high-risk neuroblastomas specimens. The Kaplan-Meier method was used to correlate the analysed elements with survival. Results: The organisation of blood vessels and reticulin fibres in neuroblastic tumours defined an ultra-high-risk patient subgr…

0301 basic medicineRiskCancer ResearchPathologymedicine.medical_specialtyblood vascularisationColorectal cancerKaplan-Meier EstimateRisk AssessmentCollagen Type IExtracellular matrix03 medical and health sciencesProstate cancerNeuroblastomaneuroblastoma0302 clinical medicineNeuroblastomamedicineHumansSurvival rateMolecular Diagnosticscollagen type I fibresbusiness.industryBrain Neoplasmsultra-high-risk neuroblastomaInfantExtracellular matrixelastic fibresmedicine.diseaseElastic TissuePrognosisSurvival RateReticulin030104 developmental biologymedicine.anatomical_structureOncologyglycosaminoglycans030220 oncology & carcinogenesisBlood Vesselsreticulin fibresBone marrowSkin cancerLiver cancerbusiness
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Mutational analysis of 105 mucopolysaccharidosis type VI patients

2007

Mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome) is a lysosomal storage disorder caused by mutations in the N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ARSB) gene. ARSB is a lysosomal enzyme involved in the degradation of the glycosaminoglycans (GAG) dermatan and chondroitin sulfate. ARSB mutations reduce enzyme function and GAG degradation, causing lysosomal storage and urinary excretion of these partially degraded substrates. Disease onset and rate of progression is variable, producing a spectrum of clinical presentation. In this study, 105 MPS VI patients—representing about 10% of the world MPS VI population—were studied for molecular genetic and biochemical parame…

AdultArylsulfatase BAdolescentN-Acetylgalactosamine-4-SulfataseMPS VIDNA Mutational AnalysisNonsense mutationMucopolysaccharidosis type VIBiologyPolymorphism Single NucleotideGenetic HeterogeneityAge DistributionGene FrequencyGenotypeGeneticsmedicineHumansMissense mutationGenetic TestingChildCells CulturedGenetics (clinical)mucopolysaccharidosis type VIGlycosaminoglycansGeneticsMucopolysaccharidosis VIGenetic heterogeneityMucopolysaccharidosis VIMiddle Agedmedicine.diseasearylsulfatase BMaroteaux–Lamy syndromeDisease ProgressionARSBMaroteaux-LamyHuman Mutation
researchProduct

Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type B

2017

To evaluate the natural course of disease progression in patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB), identify potential end points for future therapy trials, and characterize biomarkers related to the disease.A prospective, multicenter study was conducted. Baseline, 6-month, and 12-month assessments included neurodevelopmental status (Bayley Scales of Infant Development, Third edition), adaptive status (Vineland Adaptive Behavior Scales, Second Edition), volumetric brain magnetic resonance imaging, cerebrospinal fluid heparan sulfate, and urine glycosaminoglycan (GAG) measurements.Nineteen patients aged 1.6-31.7 years were enrolled. Over 12 months, cognition,…

AdultMale0301 basic medicinePediatricsmedicine.medical_specialtyAdolescentDiseaseBayley Scales of Infant DevelopmentMucopolysaccharidosis IIIYoung Adult03 medical and health sciences0302 clinical medicineMucopolysaccharidosis IIImedicineHumansLongitudinal StudiesProspective StudiesYoung adultChildProspective cohort studyCerebrospinal FluidGlycosaminoglycansSanfilippo syndromemedicine.diagnostic_testbusiness.industryBrainInfantMagnetic resonance imagingmedicine.diseaseMagnetic Resonance ImagingVineland Adaptive Behavior Scale030104 developmental biologyNeurodevelopmental DisordersChild PreschoolPediatrics Perinatology and Child HealthDisease ProgressionFemaleHeparitin SulfatebusinessBiomarkers030217 neurology & neurosurgeryThe Journal of Pediatrics
researchProduct

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical …

2008

Abstract The objective of this study was to evaluate the long-term clinical benefits and safety of recombinant human arylsulfatase B (rhASB) treatment of mucopolysaccharidosis type VI (MPS VI: Maroteaux-Lamy syndrome), a lysosomal storage disease. Fifty-six patients derived from 3 clinical studies were followed in open-label extension studies for a total period of 97–260 Weeks. All patients received weekly infusions of rhASB at 1mg/kg. Efficacy was evaluated by (1) distance walked in a 12-minute walk test (12MWT) or 6-minute walk test (6MWT), (2) stairs climbed in the 3-minute stair climb (3MSC), and (3) reduction in urinary glycosaminoglycans (GAG). Safety was evaluated by compliance, adve…

AdultMaleArylsulfatase Bmedicine.medical_specialtyAdolescentN-Acetylgalactosamine-4-SulfataseEndocrinology Diabetes and MetabolismMucopolysaccharidosis type VIWalkingMotor ActivityPlaceboBiochemistryEndocrinologyInternal medicineGeneticsmedicineHumansChildAdverse effectMolecular BiologyGlycosaminoglycansMucopolysaccharidosis VIbusiness.industryMucopolysaccharidosis VIEnzyme replacement therapymedicine.diseaseRecombinant ProteinsSurgeryClinical trialMaroteaux–Lamy syndromeTreatment OutcomeChild PreschoolFemalebusinessFollow-Up StudiesMolecular Genetics and Metabolism
researchProduct

Sulodexide and the microcirculatory component in microphlebopathies.

1992

A double-blind, placebo-controlled study was carried out in 36 patients, aged 30 to 50 years, to evaluate the effectiveness of oral sulodexide in the treatment of chronic venous insufficiency due to idiopathic varices. Patients were allocated at random to receive either oral sulodexide as 2 capsules (each containing 250 lipoproteinolipase releasing units) twice daily or 2 identical placebo capsules twice daily over a period of 45 days. Using strain gauge plethysmographic data, assessments were made of the microcirculatory effects of treatment by calculating the coefficient of capillary filtration from measurements made on both legs of each patient on entry and after 30 and 45 days of treatm…

AdultMaleChronic venous insufficiencymedicine.drug_classHemodynamicsAdministration OralPlaceboMicrocirculationDouble-Blind MethodmedicinePlethysmographHumansGlycosaminoglycansHypolipidemic Agentsbusiness.industryAnticoagulantGeneral MedicineMiddle Agedmedicine.diseaseSulodexidePlethysmographyVenous InsufficiencyAnesthesiaChronic DiseaseFemalebusinessVaricesCurrent medical research and opinion
researchProduct

Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled s…

2008

Since very little is understood about the exact aetiology of tinnitus, this has made treatment of the condition difficult. Even though approximately 10-15% of the general population suffer from tinnitus, only 2% consider it serious enough to warrant any treatment. The main problem arising from tinnitus is the disturbance it causes not only in day to day life but also in sleep, leading to fatigue and general discomfort. The present study focused on the effect of Melatonin in conjunction with Sulodexide as a treatment method for tinnitus. Overall, 102 patients suffering from tinnitus were evaluated in a prospective randomised controlled study conducted in a tertiary care ENT department. After…

AdultMaleMelatonin sulodexideAcufenometryAdministration OralTinnitus handicap inventoryOtologyHearing lossMiddle AgedTinnitusotorhinolaryngologic diseasesHumansFemaleProspective StudiesMedical treatmentGlycosaminoglycansMelatoninActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
researchProduct

The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects

2013

Abstract Objectives The objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects. Methods MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels. Results Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean ± SD height z-scores were − 5.6 ± 3.1 as determined by the CDC growth charts. Mean ± SD from the 6-minute-walk-test was 212.6 ± 152.2 m, revealing limitation…

AdultMaleVital capacitymedicine.medical_specialtyAdolescentCross-sectional studyEndocrinology Diabetes and MetabolismMucopolysaccharidosisMotor ActivityBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyElosulfase alfaQuality of lifeSurveys and QuestionnairesInternal medicineActivities of Daily LivingGeneticsmedicineHumansMedical historyRespiratory functionChildExerciseMolecular BiologyGlycosaminoglycans030304 developmental biology0303 health sciencesbusiness.industryInfant NewbornInfantMucopolysaccharidosis IVmedicine.diseaseUnited StatesRespiratory Function TestsCross-Sectional StudieschemistryKeratan SulfateChild PreschoolPhysical EnduranceQuality of LifeMucopolysaccharidosis IVPhysical therapyFemalebusiness030217 neurology & neurosurgeryMolecular Genetics and Metabolism
researchProduct